Magnera Posts $90M Q4 Operating Loss on $106M Impairment, Guides FY27 EBITDA to $390-410M
MAGN sits 65% above its 52-week low of $7.815 on elevated volume (2.8× avg).
Summary
Magnera's fiscal 2026 results show a $90 million Q4 operating loss driven by a $106 million impairment, but adjusted EBITDA rose 8% to $97 million and free cash flow hit $115 million. FY2027 guidance calls for $390-410 million of adjusted EBITDA.
Key Events · Earnings and Guidance · MAGN
-
Q4 Loss Driven by Impairment
Net sales of $851 million produced a $90 million operating loss after a $106 million goodwill and other impairment charge; adjusted EBITDA was $97 million, up 8% year over year.
-
Full-Year Cash Generation Strong
Fiscal 2026 operating cash flow of $178 million less $63 million of net capex left $115 million of free cash flow, and the company repaid $122 million of debt, bringing total debt to $1.85 billion.
-
FY2027 Guidance Issued
Management guides to adjusted EBITDA of $390-410 million (about 6% growth at the $400 million midpoint versus $378 million actual) and free cash flow of $110-130 million.
-
Volume Weakness Offset by Pricing
Q4 sales rose 1% as a $43 million pricing increase from raw-material pass-through offset a 4% organic volume decline, with soft healthcare demand in the Americas and general weakness in Europe.
Analysis · MAGN · Manufacturing
The quarter's headline loss is an accounting event, not an operating collapse: strip out the $106 million goodwill and other impairment and the business generated $97 million of adjusted EBITDA, up 8% year over year. Cash matters more here. Operations produced $178 million, funding $63 million of capex and $122 million of debt repayment, which left $115 million of free cash flow and brought debt down to $1.85 billion. Management's FY2027 guide of $390-410 million adjusted EBITDA implies roughly 6% growth at the midpoint, a modest step up that leans on Project CORE cost cuts and merger synergies rather than volume, since organic volumes fell 4% in the quarter. The risk is that the impairment signals the merger-carried goodwill is worth less than carried, and the prior 10-Q already flagged ineffective internal controls.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MAGN was trading at $12.89 on NYSE in the Manufacturing sector, with a market capitalization of approximately $445M. The 52-week trading range was $7.82 to $15.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.